Related Experiment Video
Updated: Jan 9, 2026

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
Published on: June 25, 2016
Cenobamate for Drug-Resistant Epilepsy: Initial Experience from a Single Tertiary Center
Tawfik Elsherbini1, Vanessa Léger2, Arline Aude Bérubé1,2
1Faculté de médecine, https://ror.org/0161xgx34Université de Montréal, Montreal, QC, Canada.
None:
Cenobamate (CNB) has shown efficacy in reducing seizures in drug-resistant epilepsy (DRE) in clinical trials. We conducted a retrospective study at the Centre hospitalier de l'Université de Montréal epilepsy clinic to assess CNB's real-world efficacy and safety. Among 109 patients, follow-up data were available for 68 at 3 months, 53 at 6 months and 54 at 12 months. Median seizure frequency reduction was 50.0%, 57.3% and 73.3%, respectively. Seizure freedom at 12 months was 25.9%. CNB was discontinued in 8.3% of individuals due to adverse events (non-serious) or treatment inefficacy. Our findings support CNB's effectiveness in a DRE population.
More Related Videos
Related Concept Videos
Electroconvulsive Therapy
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Glutamate Antagonists

